search
Back to results

Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis

Primary Purpose

Pulmonary Fibrosis

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
oxygen
medical air
Sponsored by
University of Siena
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pulmonary Fibrosis focused on measuring Oxygen therapy

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pulmonary fibrosis of any cause
  • Oxygen saturation => 90% at rest in ambient air, and <88% during walking test

Exclusion Criteria:

  • Inability to give consent
  • Walking impaired by any condition except pulmonary disease

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    oxygen

    medical air

    Arm Description

    oxygen administered through a nasal cannula at a personalized, fixed flow

    Medical air administered through a nasal cannula at the same flow

    Outcomes

    Primary Outcome Measures

    distance walked
    recorded by operator
    Difference in preference of the two treatments compared to no treatment.
    VAS scale

    Secondary Outcome Measures

    Difference in oxygen saturation level
    Digitally recorded
    Difference in heart rate
    Digitally recorded
    Difference in dyspnea at the end of test
    VAS
    Difference in fatigue at the end of test
    VAS
    Preference between the two treatments
    VAS

    Full Information

    First Posted
    January 22, 2016
    Last Updated
    January 28, 2016
    Sponsor
    University of Siena
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02668029
    Brief Title
    Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
    Official Title
    Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis Normoxemic at Rest Who Desaturate on Exercise
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2012 (undefined)
    Primary Completion Date
    April 2013 (Actual)
    Study Completion Date
    April 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Siena

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Patients with pulmonary fibrosis often desaturate on exercise. There are no data showing whether ambulatory oxygen can be useful to improve exercise capacity in this condition. Ambulatory ambulatory oxygen is often denied to these patients based on studies conducted on patients with chronic obstructive pulmonary disease, a completely different condition for physiopathology, prognosis, and response to therapy. We therefore planned a controlled study to verify the usefulness of ambulatory oxygen in patients with pulmonary fibrosis
    Detailed Description
    Criteria for inclusion: Patients with a diagnosis of pulmonary fibrosis of any kind, with oxygen saturation >90% in ambient air at rest, showing a desaturation <88% during a preliminary 6 minutes walking test Criteria for exclusion: Inability to give consent, age <18 or >85 years, walking problems from causes different from pulmonary disease Procedure: In a preliminary session, the flow of oxygen needed to prevent desaturation during walking is established according to a validated protocol Guyatt et al, Am J Respir Crit Care Med 2001,163:,942-946.) Two 6 minutes walking tests are then performed in a corridor, at least 30' apart, during administration of oxygen or medical air, in random order and double blind, at the same pre-determined flow, administered through a nasal cannula connected to a wall outlet (concealed from sight, being in a side rum at about mid distance in the corridor) through a 10 mt plastic tubing. Oxygen saturation and pulse rate are monitored through a dedicated recording oximeter (Minoxy, Cosmed) , whose display is concealed to both the patient and the operator, with an alarm set for oxygen saturation <70%, to stop the test in case severe desaturation would occur Data are then transferred to computer for analysis only after both test are performed. Walked distance is recorded by the operator unaware of treatment. At the end of each test, a short questionnaire is administered with 10 cm Visual Analogue Scales (VAS) for dyspnoea, fatigue, and preference compared to performing the test without any treatment. At the end of the second test a further scale is submitted, asking about the preference between the two treatments. Primary outcomes are the distance walked and the difference in preference of the two treatments compared o no treatment. Secondary outcomes are differences in minimal saturation level and maximal pulse rate during the test and in the report of dyspnea and fatigue at the end of the test, and the reported preference between the two treatments. Statistical analysis to evaluate the effect of the treatment on walking distance, heart frequency and oxygen saturation is performed using generalized linear model with a gaussian family and identity link and including order of treatment as a fixed effect. Parameters evaluated using VAS are analyzed using Koch adaptation of Wilkoxon rank test (Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002)

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pulmonary Fibrosis
    Keywords
    Oxygen therapy

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Phase 2
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    32 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    oxygen
    Arm Type
    Experimental
    Arm Description
    oxygen administered through a nasal cannula at a personalized, fixed flow
    Arm Title
    medical air
    Arm Type
    Placebo Comparator
    Arm Description
    Medical air administered through a nasal cannula at the same flow
    Intervention Type
    Drug
    Intervention Name(s)
    oxygen
    Other Intervention Name(s)
    ambulatory oxygen
    Intervention Description
    information already included in arm/group descriptions.
    Intervention Type
    Drug
    Intervention Name(s)
    medical air
    Other Intervention Name(s)
    Placebo
    Intervention Description
    Placebo
    Primary Outcome Measure Information:
    Title
    distance walked
    Description
    recorded by operator
    Time Frame
    end of test (6 minutes)
    Title
    Difference in preference of the two treatments compared to no treatment.
    Description
    VAS scale
    Time Frame
    end of test (6 minutes)
    Secondary Outcome Measure Information:
    Title
    Difference in oxygen saturation level
    Description
    Digitally recorded
    Time Frame
    Walking test (6 min)
    Title
    Difference in heart rate
    Description
    Digitally recorded
    Time Frame
    Walking test (6 min)
    Title
    Difference in dyspnea at the end of test
    Description
    VAS
    Time Frame
    End of test (6 min)
    Title
    Difference in fatigue at the end of test
    Description
    VAS
    Time Frame
    End of test (6 min)
    Title
    Preference between the two treatments
    Description
    VAS
    Time Frame
    End of both tests (45 min)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Pulmonary fibrosis of any cause Oxygen saturation => 90% at rest in ambient air, and <88% during walking test Exclusion Criteria: Inability to give consent Walking impaired by any condition except pulmonary disease
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Piersante Sestini, MD
    Organizational Affiliation
    University of Siena
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    15901604
    Citation
    Guyatt GH, Nonoyama M, Lacchetti C, Goeree R, McKim D, Heels-Ansdell D, Goldstein R. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J Respir Crit Care Med. 2005 Sep 1;172(5):573-80. doi: 10.1164/rccm.200412-1692OC. Epub 2005 May 18.
    Results Reference
    background
    Links:
    URL
    http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0471496537.html
    Description
    Senn SS. Cross-over Trials in Clinical Research, 2nd Edition. Wiley 2002

    Learn more about this trial

    Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis

    We'll reach out to this number within 24 hrs